Back to News
Market Impact: 0.28
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
TG Therapeutics said its multiple sclerosis therapy BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and continues to gain share approaching its fourth full year on the market. The market-share momentum supports a favorable commercial trajectory for the company’s key drug franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
TGTX0.72
More News
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic’s first embedded evaluator is … Accenture?
- Volkswagen and Porsche Holding cut outlook
- Warren Buffett steps down as Berkshire Hathaway chairman
- Meet Warren Buffett’s son Howard, a former sheriff, war photographer, and now, Berkshire’s new chairman